Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2026 07:30 ET | Source: Annovis Bio Inc.

Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026

MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...
May 06, 2026 10:34 ET | Source: Research and Markets

Microbiomics in Clinical Trials Training Course (ONLINE EVENT: Sept 14, 2026)

Dublin, May 06, 2026 (GLOBE NEWSWIRE) -- The "Microbiomics in Clinical Trials (Sept 14, 2026)" training has been added to ResearchAndMarkets.com's offering.The microbiome plays an important role in...
May 06, 2026 09:20 ET | Source: Research and Markets

Systemic Lupus Erythematosus - Global Clinical Trials Review 2026, Segmented by Region, Country (G7 & E7), Trial Status, Phase, Sponsor Type, and Endpoint Status

Dublin, May 06, 2026 (GLOBE NEWSWIRE) -- The "Systemic Lupus Erythematosus - Global Clinical Trials Review, 2026" has been added to ResearchAndMarkets.com's offering. The report delivers an...
May 01, 2026 09:40 ET | Source: Research and Markets

Clinical Trials Market Insights and Growth Outlook to 2033 - Shift Towards Patient-Centric and Technology-Driven Trial Models Transforming the Industry

Dublin, May 01, 2026 (GLOBE NEWSWIRE) -- The "Clinical Trials Market Insights, Competitive Landscape, and Market Forecast - 2033" has been added to ResearchAndMarkets.com's offering. The global...
May 01, 2026 07:00 ET | Source: MapLight Therapeutics, Inc.

MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results

Enrollment completed in ML-007C-MA’s ZEPHYR Phase 2 trial in schizophrenia Last patient visit completed for ML-004’s IRIS Phase 2 trial in autism spectrum disorderTopline results from both Phase 2...
April 30, 2026 08:30 ET | Source: VVT Med Inc.

VVT Med Announces Positive Clinical Data for ScleroSafe(R) Published in Peer-Reviewed Indian Journal of Vascular and Endovascular Surgery

VANCOUVER, BC, April 30, 2026 (GLOBE NEWSWIRE) -- VVT Med Inc. (TSXV: VVTM) ("VVT Med" or the "Company"), a developer of minimally invasive, non-thermal, non-tumescent ("NT-NT") solutions for venous...
April 30, 2026 07:00 ET | Source: Novartis Pharma AG

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North Carolina...
April 30, 2026 07:00 ET | Source: Novartis Pharma AG

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North Carolina...
April 28, 2026 13:49 ET | Source: FDA

FDA Announces Major Steps to Implement Real-Time Clinical Trials

White Oak, Md., April 28, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today announced two major steps as part of an initiative to advance the implementation of real-time clinical...
April 28, 2026 12:02 ET | Source: Quoin Pharmaceuticals, Inc.

CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia...